Sugi Predict

Sugi Predict / Compounds / SCHEMBL21757013

SCHEMBL21757013

SCHEMBL21757013

CC(C)(C)OC(=O)N1CC2(CC=C(B3OC(C)(C)C(C)(C)O3)C2)C1

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 2/20 0.39
▸ NR1H2 P55055 1/20 0.38
▸ ACACB O00763 5/20 0.35
▸ GPR183 P32249 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ SCD5 Q86SK9 1/20 0.34
▸ CYP11B2 P19099 1/20 0.33
▸ GPR119 Q8TDV5 1/20 0.33
▸ RORC P51449 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33
▸ HDAC2 Q92769 2/20 0.32
▸ HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19693266 0.91 SCD5 (0.42) USP30NR1H2ACACBGPR183USP2
SCHEMBL23584405 0.88 USP30 (0.40) USP30ACACBGPR183USP2SMN1; SMN2
SCHEMBL21060289 0.88 USP30 (0.38) USP30NR1H2ACACBGPR183USP2
SCHEMBL26963358 0.88 USP30 (0.38) USP30NR1H2ACACBGPR183USP2
SCHEMBL26134743 0.83 SCD5 (0.42) USP30NR1H2ACACBGPR183SCD5
SCHEMBL25411921 0.82 P2RX7 (0.37) P2RX7
SCHEMBL23931390 0.81 USP30 (0.41) USP30NR1H2GPR183USP2SMN1; SMN2
SCHEMBL16051476 0.81 USP30 (0.40) USP30ACACBGPR183USP2SMN1; SMN2
SCHEMBL1763807 0.77 USP30 (0.41) USP30NR1H2USP2SMN1; SMN2P2RX7
SCHEMBL23766340 0.76 NR1H2 (0.41) NR1H2ACACBGPR183USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4674484-A2 THIENOPYRROLE COMPOUNDS Gilead Sciences, Inc. (US) 2026-01-07 — — EP disclosed
EP-4291562-B1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES INC (US) 2025-09-10 — — EP disclosed
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 — — EP disclosed
US-20240217990-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2024-07-04 — — US disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 — — US disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 — — US disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 — — US disclosed
WO-2024002284-A1 FIVE-MEMBERED AND SIX-MEMBERED NITROGEN-CONTAINING COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF 杭州圣域生物医药科技有限公司 2024-01-04 — — WO disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 — — US disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 — — US disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 — — US disclosed
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
WO-2022063784-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 — — WO disclosed
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 — — US disclosed
WO-2021216661-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV ASSEMBLY BIOSCIENCES, INC. (US) 2021-10-28 — — WO disclosed
WO-2021159372-A1 USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES 珠海联邦制药股份有限公司 2021-08-19 — — WO disclosed
US-20210155621-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF ZHUHAI UNITED LABORATORIES CO., LTD. (CN) 2021-05-27 — — US disclosed
WO-2020038457-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF 珠海联邦制药股份有限公司 2020-02-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217990-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 USP30 4555/4885NR1H2 1364/4885ACACB 1197/4885
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP USP30 1037/4885NR1H2 186/4885ACACB 61/4885
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP USP30 986/4885NR1H2 193/4885ACACB 60/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP USP30 986/4885NR1H2 193/4885ACACB 60/4885
US-20210155621-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF JAK1, JAK2, TYK2 USP30 2873/4885NR1H2 3957/4885ACACB 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback